Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1Phase 1/2 1

Status

Completed 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4Genitourinary 1

Conditions

Breast Neoplasms 4Neoplasms 3Neoplasm Metastasis 2Triple Negative Breast Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Malignant Solid Tumour 1Leukemia, Myeloid, Acute 1Hamartoma Syndrome, Multiple 1Glioblastoma 1Castration-resistant Prostate Cancer 1Carcinoma, Renal Cell 1Breast Diseases 1Brain Neoplasms 1Advanced Solid Tumor 1

Interventions

Paclitaxel 81Trastuzumab 76Fulvestrant 55Cyclophosphamide 49Capecitabine 42Lapatinib 40pembrolizumab 38Docetaxel 38palbociclib 36Carboplatin 32Letrozole 28olaparib 23Doxorubicin 23Gemcitabine 21Taxes 20Everolimus 20ribociclib 19abemaciclib 19Ado-Trastuzumab Emtansine 18pertuzumab 17Radiotherapy 17Magnetic Resonance Spectroscopy 17Bevacizumab 16130-nm albumin-bound paclitaxel 16exemestane 15Vinorelbine 15Cisplatin 15veliparib 14Biopsy 14Alpelisib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Breast Neoplasms × dactolisib × Clear all
NCT01482156 2020-12-21

Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
46 enrolled
BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell

NCT00620594 2020-12-09

A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer

Novartis

Phase 1 Completed
183 enrolled
Breast

Breast Diseases, Breast Neoplasms, Hamartoma Syndrome, Multiple, Neoplasms

NCT01471847 2020-12-09

A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab

Novartis

Phase 1 Completed
5 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01248494 2016-07-25

PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer

Vanderbilt-Ingram Cancer Center

Phase 1 Completed
72 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡